SlideShare a Scribd company logo
Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Lupus Medications and
Treatment Options1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
DHEA: dehydroepiandrosterone; NSAID: nonsteroidal anti-inflammatory drugs.
1. https://www.hopkinslupus.org/lupus-treatment/. Accessed May 11, 2018.
NSAIDs
•	 These anti-inflammatory medications relieve some lupus symptoms by reducing the inflammation
responsible for the stiffness and discomfort in your muscles, joints, and other tissues
•	 NSAIDs are milder than many other lupus drugs and may be taken either alone to treat a mild flare
or in combination with other medications
Antimalarial drugs
•	 Plaquenil (hydroxychloroquine) and other antimalarials are the key to controlling lupus long term,
and some lupus patients may be on Plaquenil for the rest of their lives; for this reason, you can
think of antimalarials as a sort of “lupus life insurance”
Steroids
•	 Synthetic cortisone medications are some of the most effective treatments for reducing the
swelling, warmth, pain, and tenderness associated with the inflammation of lupus; cortisone
usually works quickly to relieve these symptoms
•	 However, cortisone can also cause many unwelcome side effects, so it is usually prescribed only
when other medications—specifically NSAIDs and anti-malarials—are not sufficient enough to
control lupus
Immunosuppressive medications
•	 Immunosuppressives are medications that help suppress the immune system; many were
originally used in patients who received organ transplants to help prevent their bodies from
rejecting the transplanted organ
•	 However, these drugs (eg, methotrexate, azathioprine, belimumab) are now also used for the
treatment of certain autoimmune diseases, such as lupus and rheumatoid arthritis
DHEA
•	 DHEA is a mild male hormone that is effective in treating some of the symptoms of mild to
moderate lupus, including hair loss (alopecia), joint pain, fatigue, and cognitive dysfunction
(eg, difficulty thinking, memory loss, distractibility, difficulty in multitasking); DHEA can also be
effective against osteoporosis
Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Systemic Lupus International
Collaborating Clinics (SLICC)
Classification Criteria for Systemic
Lupus Erythematosus1
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
ANA: antinuclear antibody; C3: complement 3; C4: complement 4; CH50: total complement; dsDNA: double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; IgA: immunoglobulin A;
IgG: immunoglobulin G; IgM: immunoglobulin M; RPR: rapid plasma regain; SLE: systemic lupus erythematosus; Sm: Smith antibody.
1. Petri M et al. Arthritis Rheum. 2012 ;64:2677-2686.
PRACTICE AID
Clinical Criteria
1.	 Acute/subacute cutaneous lupus
	 Lupus malar rash (do not count if malar discoid)
	 Bullous lupus
	 Toxic epidermal necrolysis variant of SLE
	 Maculopapular lupus rash
	 Photosensitive lupus rash (in the absence of dermatomyositis) OR subacute cutaneous lupus (nonindurated psoriaform and/or
	 annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)
2.	 Chronic cutaneous lupus
	 Classic discoid rash (localized [above the neck] or generalized [above and below the neck]), hypertrophic (verrucous) lupus, lupus
	 panniculitis (profundus), mucosal lupus, lupus erythematosus tumidus, chilblains lupus, OR discoid lupus/lichen planus overlap
3.	 Oral ulcers (palate [buccal or tongue]) OR nasal ulcers (in the absence of other causes, such as vasculitis, Behçet's disease, infection
[herpesvirus], inflammatory bowel disease, reactive arthritis, and acidic foods)
4.	 Nonscarring alopecia
	 Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes, such as alopecia areata, drugs, iron deficiency, and
	 androgenic alopecia)
5.	 Synovitis involving 2 or more joints, characterized by swelling or effusion OR tenderness in 2 or more joints and
30 minutes or more of morning stiffness
6.	 Serositis
	 Typical pleurisy for more than 1 day, pleural effusions, or pleural rub, OR typical pericardial pain (pain with recumbency improved by sitting
	 forward) for more than 1 day, pericardial effusion, pericardial rub, OR pericarditis by electrocardiography (in the absence of other causes,
	 such as infection, uremia, and Dressler's syndrome)
7.	 Renal
	 Urine protein/creatinine (or 24-hour urine protein) representing at least 500 mg of protein/24 hours OR red blood cell casts
8.	 Neurologic: seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or cranial neuropathy, cerebritis
(acute confusional state)
9.	 Hemolytic anemia
10.	 Leukopenia (<4,000/mm3
at least once) OR lymphopenia (<1,000/mm3
at least once)
11.	 Thrombocytopenia (<100,000/mm3
) at least once
Immunologic Criteria
1.	 ANA above laboratory reference range
2.	 Anti-dsDNA above laboratory reference range, except ELISA (twice above laboratory reference range)
3.	 Anti-Sm
4.	 Antiphospholipid antibody, determined by any of the following
	 Lupus anticoagulant
	 False-positive RPR
	 Medium- or high-titer anticardiolipin (IgA, IgG, or IgM)
	 Anti-β2-glycoprotein 1 (IgA, IgG, or IgM)
5.	 Low complement
	 Low C3
	 Low C4
	 Low CH50
6.	 Direct Coombs test (in the absence of hemolytic anemia)
Classify a patient as having SLE if
•	 The patient satisfies four of the criteria listed in the table above, including at least one clinical criterion and one
immunologic criterion
OR
•	 The patient has biopsy-proven nephritis compatible with SLE and with ANA or anti-dsDNA antibodies
Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Common Medications for Other
Conditions in People With Lupus1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Aspirin
•	 Low doses of aspirin are often recommended for lupus patients who have antiphospholipid antibodies
and may reduce the risk of heart attack and stroke
Antidepressants
•	 Antidepressant medications are used to treat depression and anxiety, which is present in almost half of all
people who have lupus
•	 It is important that you speak with your doctor if you feel you are experiencing clinical depression,
because many people who are physically ill respond well to antidepressant medications; in addition,
your doctor may treat your depression in different ways depending on the cause
Antiplatelet medications (platelet antagonists)
•	 Some lupus patients are at an increased risk for blood clots because of the prevalence of a condition
known as antiphospholipid antibody syndrome (APS); platelet antagonists help prevent these clots and,
in doing so, also help to prevent heart attack, stroke, and other complications
Osteoporosis medications (bisphosphonates)
•	 Bisphosponates are medications used to treat and prevent osteoporosis; people with lupus are at an
increased risk for this condition because of the inflammation they experience with the disease
•	 Certain medications taken by lupus patients also increase the risk of osteoporosis, especially
corticosteroids such as prednisone
Blood pressure medications (antihypertensives)
•	 25% to 30% of people with lupus experience hypertension (high blood pressure); the most common
causes of high blood pressure in people with lupus are kidney disease and long-term steroid use
•	 Other medications, such as cyclosporine (Neoral, Sandimmune, Gengraf) can also cause elevations in
blood pressure
•	 It is important to remember that while diet and exercise are extremely important for optimal cardiovascular
health, these elements alone may be insufficient in controlling your blood pressure; in this case, your doctor
will prescribe a medication
Anticoagulants
•	 Anticoagulants (“blood thinners”) are medications that decrease the ability of the blood to clot and are
used in lupus patients with antiphospholipid antibodies to reduce the risk of deep venous thrombosis
(DVT), stroke, and heart attack
Gastrointestinal medications
•	 Many people with lupus suffer from gastrointestinal problems, especially heartburn caused by
gastroesophageal reflux disease (GERD); peptic ulcers can also occur, often because of certain medications
used in lupus treatment, including NSAIDs and steroids
•	 Certain medications may be prescribed or recommended by your doctor to control these conditions
Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Common Medications for Other
Conditions in People With Lupus1
PRACTICE AID
1. https://www.hopkinslupus.org/lupus-treatment/. Accessed May 11, 2018.
Cholesterol medications (statins)
•	 Statins are medications that lower the level of cholesterol in your blood by reducing the production
of cholesterol in the liver; people with high levels of cholesterol in their blood face an increased risk of
cardiovascular disease, which can lead to chest pain, heart attack, stroke, and peripheral vascular disease
•	 Studies have shown that people with lupus are more likely to have clogged arteries that can lead to heart
attack and stroke at a younger age; this increased risk is caused by elevated cholesterol levels, high blood
pressure, diabetes, and inflammation, conditions that occur often in people with lupus
•	 Certain medications, such as corticosteroids (eg, prednisone), can provoke or compound these symptoms;
for this reason, the cholesterol-lowering properties of statins are commonly called upon for lupus patients
Thyroid medications
•	 Autoimmune thyroid disease is common in lupus; it is believed that about 6% of people with lupus have
hypothyroidism (underactive thyroid) and about 2% have hyperthyroidism (overactive thyroid)
•	 A thyroid gland that is functioning improperly can affect the function of organs such as the brain, heart,
kidneys, liver, and skin
•	 Hypothyroidism can cause weight gain, fatigue, depression, moodiness, and dry hair and skin;
hyperthyroidism can cause weight loss, heart palpitations, tremors, and heat intolerance, and can
eventually lead to osteoporosis
•	 Treatment for both underactive and overactive thyroid involves getting your body’s metabolism back
to normal
Fibromyalgia medications
•	 Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness, general fatigue,
and nonrestful sleep
•	 Many people with lupus have fibromyalgia; in fact, much of the pain that people with lupus feel is because
of this condition
•	 Three medications are used to reduce some of the physical and emotional symptoms of fibromyalgia
Restasis (dry eye medication)
•	 Restasis is an immunosuppressive medication used to treat eye symptoms related to Sjogren’s syndrome,
a chronic autoimmune disorder in which the glands that produce tears and saliva do not function correctly
Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical
Guidance for the Primary Care Physician,”at www.peerview.com/FYE40.
Information for Patients:
Lifestyle Information1
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
1. https://www.hopkinslupus.org/lupus-info/lifestyle-additional-information/. Accessed May 11, 2018.
THINGS TO
AVOID
Sunlight
Echinacea
Bactrim and Septra
(sulfamethoxazole and
trimethoprim)
Alfalfa sprouts
Melatonin and
Rozerem (ramelteon)
Garlic

More Related Content

What's hot

Recent Advances in migraine
Recent Advances in migraine Recent Advances in migraine
Recent Advances in migraine
DR ANUP PETARE
 
Anti pyretics
Anti pyreticsAnti pyretics
Anti pyretics
Kalaivanisathishr
 
Diabetic neuropathy
Diabetic neuropathyDiabetic neuropathy
Diabetic neuropathy
Fahad AlHulaibi
 
Hanipsych, antipsychotics and antidepressants action
Hanipsych, antipsychotics and antidepressants actionHanipsych, antipsychotics and antidepressants action
Hanipsych, antipsychotics and antidepressants action
Hani Hamed
 
1. migraine management cme final 2018
1. migraine management cme final 20181. migraine management cme final 2018
1. migraine management cme final 2018
DrArun Kumar
 
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopital
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopitalInpatient Diabetes Management - How to Control Hyperglycemia inhsopital
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopital
Usama Ragab
 
Tues 11am wrobel new antiseizure meds
Tues 11am wrobel new antiseizure medsTues 11am wrobel new antiseizure meds
Tues 11am wrobel new antiseizure meds
NCProvidersCouncil
 

What's hot (8)

Recent Advances in migraine
Recent Advances in migraine Recent Advances in migraine
Recent Advances in migraine
 
Anti pyretics
Anti pyreticsAnti pyretics
Anti pyretics
 
Managament Of Migraine
Managament Of MigraineManagament Of Migraine
Managament Of Migraine
 
Diabetic neuropathy
Diabetic neuropathyDiabetic neuropathy
Diabetic neuropathy
 
Hanipsych, antipsychotics and antidepressants action
Hanipsych, antipsychotics and antidepressants actionHanipsych, antipsychotics and antidepressants action
Hanipsych, antipsychotics and antidepressants action
 
1. migraine management cme final 2018
1. migraine management cme final 20181. migraine management cme final 2018
1. migraine management cme final 2018
 
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopital
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopitalInpatient Diabetes Management - How to Control Hyperglycemia inhsopital
Inpatient Diabetes Management - How to Control Hyperglycemia inhsopital
 
Tues 11am wrobel new antiseizure meds
Tues 11am wrobel new antiseizure medsTues 11am wrobel new antiseizure meds
Tues 11am wrobel new antiseizure meds
 

Similar to Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician

Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...
Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...
Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...
PVI, PeerView Institute for Medical Education
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
Fatima Elsamani
 
Lupus
LupusLupus
SYSTEMIC LUPUS ERYTHROMATOSUS
SYSTEMIC LUPUS ERYTHROMATOSUSSYSTEMIC LUPUS ERYTHROMATOSUS
SYSTEMIC LUPUS ERYTHROMATOSUS
bandaru pratyusha
 
PalliativeCareResourceALS.ppt
PalliativeCareResourceALS.pptPalliativeCareResourceALS.ppt
PalliativeCareResourceALS.ppt
ssuser0c40b4
 
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)
Anant Layall
 
Rehabilitation in myopathies - dr venugopal kochiyil
Rehabilitation in myopathies  - dr venugopal kochiyilRehabilitation in myopathies  - dr venugopal kochiyil
Rehabilitation in myopathies - dr venugopal kochiyil
mrinal joshi
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
Aziz aziz
 
MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...
MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...
MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...
ericss1234_msvn
 
SLE TX.pptx dr.riffat anasari civil hospital
SLE TX.pptx dr.riffat anasari civil hospitalSLE TX.pptx dr.riffat anasari civil hospital
SLE TX.pptx dr.riffat anasari civil hospital
RAMJIBANYADAV2
 
Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
Paige Abrams
 
Heart Failure (HF)
Heart Failure (HF)Heart Failure (HF)
Heart Failure (HF)
Divya Watson
 
6256483.ppt nursing medical surgical nursing
6256483.ppt nursing  medical surgical nursing6256483.ppt nursing  medical surgical nursing
6256483.ppt nursing medical surgical nursing
ssuser47b89a
 
Drug presentation
Drug presentationDrug presentation
Drug presentation
Alisha Talwar
 
BIO GROUP PROJECT.pptx
BIO GROUP PROJECT.pptxBIO GROUP PROJECT.pptx
BIO GROUP PROJECT.pptx
ssuser7b03941
 
Medical Emergency Prevention and Preparedness
Medical Emergency Prevention and PreparednessMedical Emergency Prevention and Preparedness
Medical Emergency Prevention and Preparedness
Neil Pande
 

Similar to Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician (20)

Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...
Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...
Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment...
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Lupus
LupusLupus
Lupus
 
Lupus
LupusLupus
Lupus
 
SYSTEMIC LUPUS ERYTHROMATOSUS
SYSTEMIC LUPUS ERYTHROMATOSUSSYSTEMIC LUPUS ERYTHROMATOSUS
SYSTEMIC LUPUS ERYTHROMATOSUS
 
lupus presentation final
lupus presentation finallupus presentation final
lupus presentation final
 
Lupus
LupusLupus
Lupus
 
PalliativeCareResourceALS.ppt
PalliativeCareResourceALS.pptPalliativeCareResourceALS.ppt
PalliativeCareResourceALS.ppt
 
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)
 
Rehabilitation in myopathies - dr venugopal kochiyil
Rehabilitation in myopathies  - dr venugopal kochiyilRehabilitation in myopathies  - dr venugopal kochiyil
Rehabilitation in myopathies - dr venugopal kochiyil
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Lupus a
Lupus aLupus a
Lupus a
 
MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...
MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...
MULTIPLE SCLEROSIS SYMPTOM MANAGEMENT & EMERGING THERAPIES, Bertha C. Fonseca...
 
SLE TX.pptx dr.riffat anasari civil hospital
SLE TX.pptx dr.riffat anasari civil hospitalSLE TX.pptx dr.riffat anasari civil hospital
SLE TX.pptx dr.riffat anasari civil hospital
 
Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
 
Heart Failure (HF)
Heart Failure (HF)Heart Failure (HF)
Heart Failure (HF)
 
6256483.ppt nursing medical surgical nursing
6256483.ppt nursing  medical surgical nursing6256483.ppt nursing  medical surgical nursing
6256483.ppt nursing medical surgical nursing
 
Drug presentation
Drug presentationDrug presentation
Drug presentation
 
BIO GROUP PROJECT.pptx
BIO GROUP PROJECT.pptxBIO GROUP PROJECT.pptx
BIO GROUP PROJECT.pptx
 
Medical Emergency Prevention and Preparedness
Medical Emergency Prevention and PreparednessMedical Emergency Prevention and Preparedness
Medical Emergency Prevention and Preparedness
 

More from PVI, PeerView Institute for Medical Education

Adapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use DisorderAdapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use Disorder
PVI, PeerView Institute for Medical Education
 
Adapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use DisorderAdapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use Disorder
PVI, PeerView Institute for Medical Education
 
Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...
Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...
Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...
PVI, PeerView Institute for Medical Education
 
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
PVI, PeerView Institute for Medical Education
 
Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...
Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...
Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...
PVI, PeerView Institute for Medical Education
 
Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...
Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...
Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...
PVI, PeerView Institute for Medical Education
 
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
PVI, PeerView Institute for Medical Education
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
PVI, PeerView Institute for Medical Education
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
PVI, PeerView Institute for Medical Education
 
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
PVI, PeerView Institute for Medical Education
 
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
PVI, PeerView Institute for Medical Education
 
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
PVI, PeerView Institute for Medical Education
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
PVI, PeerView Institute for Medical Education
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
PVI, PeerView Institute for Medical Education
 
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
PVI, PeerView Institute for Medical Education
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
PVI, PeerView Institute for Medical Education
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
PVI, PeerView Institute for Medical Education
 
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
PVI, PeerView Institute for Medical Education
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
PVI, PeerView Institute for Medical Education
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
PVI, PeerView Institute for Medical Education
 

More from PVI, PeerView Institute for Medical Education (20)

Adapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use DisorderAdapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use Disorder
 
Adapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use DisorderAdapting HIV Treatment for People With Substance Use Disorder
Adapting HIV Treatment for People With Substance Use Disorder
 
Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...
Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...
Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evo...
 
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?
 
Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...
Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...
Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to...
 
Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...
Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...
Stories Behind the Science in Non-Cystic Fibrosis Bronchiectasis: Understandi...
 
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
Establishing the Collaborative Benchmark for HCC Care: Critical Discussions B...
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
 
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...
 
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...
 
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...
 
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
 
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...
 
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic St...
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
 
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...
 
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
 
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...
 

Recently uploaded

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 

Recently uploaded (20)

Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 

Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician

  • 1. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician,”at www.peerview.com/FYE40. Information for Patients: Lupus Medications and Treatment Options1 PRACTICE AID This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. DHEA: dehydroepiandrosterone; NSAID: nonsteroidal anti-inflammatory drugs. 1. https://www.hopkinslupus.org/lupus-treatment/. Accessed May 11, 2018. NSAIDs • These anti-inflammatory medications relieve some lupus symptoms by reducing the inflammation responsible for the stiffness and discomfort in your muscles, joints, and other tissues • NSAIDs are milder than many other lupus drugs and may be taken either alone to treat a mild flare or in combination with other medications Antimalarial drugs • Plaquenil (hydroxychloroquine) and other antimalarials are the key to controlling lupus long term, and some lupus patients may be on Plaquenil for the rest of their lives; for this reason, you can think of antimalarials as a sort of “lupus life insurance” Steroids • Synthetic cortisone medications are some of the most effective treatments for reducing the swelling, warmth, pain, and tenderness associated with the inflammation of lupus; cortisone usually works quickly to relieve these symptoms • However, cortisone can also cause many unwelcome side effects, so it is usually prescribed only when other medications—specifically NSAIDs and anti-malarials—are not sufficient enough to control lupus Immunosuppressive medications • Immunosuppressives are medications that help suppress the immune system; many were originally used in patients who received organ transplants to help prevent their bodies from rejecting the transplanted organ • However, these drugs (eg, methotrexate, azathioprine, belimumab) are now also used for the treatment of certain autoimmune diseases, such as lupus and rheumatoid arthritis DHEA • DHEA is a mild male hormone that is effective in treating some of the symptoms of mild to moderate lupus, including hair loss (alopecia), joint pain, fatigue, and cognitive dysfunction (eg, difficulty thinking, memory loss, distractibility, difficulty in multitasking); DHEA can also be effective against osteoporosis
  • 2. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician,”at www.peerview.com/FYE40. Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria for Systemic Lupus Erythematosus1 This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. ANA: antinuclear antibody; C3: complement 3; C4: complement 4; CH50: total complement; dsDNA: double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M; RPR: rapid plasma regain; SLE: systemic lupus erythematosus; Sm: Smith antibody. 1. Petri M et al. Arthritis Rheum. 2012 ;64:2677-2686. PRACTICE AID Clinical Criteria 1. Acute/subacute cutaneous lupus Lupus malar rash (do not count if malar discoid) Bullous lupus Toxic epidermal necrolysis variant of SLE Maculopapular lupus rash Photosensitive lupus rash (in the absence of dermatomyositis) OR subacute cutaneous lupus (nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias) 2. Chronic cutaneous lupus Classic discoid rash (localized [above the neck] or generalized [above and below the neck]), hypertrophic (verrucous) lupus, lupus panniculitis (profundus), mucosal lupus, lupus erythematosus tumidus, chilblains lupus, OR discoid lupus/lichen planus overlap 3. Oral ulcers (palate [buccal or tongue]) OR nasal ulcers (in the absence of other causes, such as vasculitis, Behçet's disease, infection [herpesvirus], inflammatory bowel disease, reactive arthritis, and acidic foods) 4. Nonscarring alopecia Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes, such as alopecia areata, drugs, iron deficiency, and androgenic alopecia) 5. Synovitis involving 2 or more joints, characterized by swelling or effusion OR tenderness in 2 or more joints and 30 minutes or more of morning stiffness 6. Serositis Typical pleurisy for more than 1 day, pleural effusions, or pleural rub, OR typical pericardial pain (pain with recumbency improved by sitting forward) for more than 1 day, pericardial effusion, pericardial rub, OR pericarditis by electrocardiography (in the absence of other causes, such as infection, uremia, and Dressler's syndrome) 7. Renal Urine protein/creatinine (or 24-hour urine protein) representing at least 500 mg of protein/24 hours OR red blood cell casts 8. Neurologic: seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or cranial neuropathy, cerebritis (acute confusional state) 9. Hemolytic anemia 10. Leukopenia (<4,000/mm3 at least once) OR lymphopenia (<1,000/mm3 at least once) 11. Thrombocytopenia (<100,000/mm3 ) at least once Immunologic Criteria 1. ANA above laboratory reference range 2. Anti-dsDNA above laboratory reference range, except ELISA (twice above laboratory reference range) 3. Anti-Sm 4. Antiphospholipid antibody, determined by any of the following Lupus anticoagulant False-positive RPR Medium- or high-titer anticardiolipin (IgA, IgG, or IgM) Anti-β2-glycoprotein 1 (IgA, IgG, or IgM) 5. Low complement Low C3 Low C4 Low CH50 6. Direct Coombs test (in the absence of hemolytic anemia) Classify a patient as having SLE if • The patient satisfies four of the criteria listed in the table above, including at least one clinical criterion and one immunologic criterion OR • The patient has biopsy-proven nephritis compatible with SLE and with ANA or anti-dsDNA antibodies
  • 3. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician,”at www.peerview.com/FYE40. Information for Patients: Common Medications for Other Conditions in People With Lupus1 PRACTICE AID This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. Aspirin • Low doses of aspirin are often recommended for lupus patients who have antiphospholipid antibodies and may reduce the risk of heart attack and stroke Antidepressants • Antidepressant medications are used to treat depression and anxiety, which is present in almost half of all people who have lupus • It is important that you speak with your doctor if you feel you are experiencing clinical depression, because many people who are physically ill respond well to antidepressant medications; in addition, your doctor may treat your depression in different ways depending on the cause Antiplatelet medications (platelet antagonists) • Some lupus patients are at an increased risk for blood clots because of the prevalence of a condition known as antiphospholipid antibody syndrome (APS); platelet antagonists help prevent these clots and, in doing so, also help to prevent heart attack, stroke, and other complications Osteoporosis medications (bisphosphonates) • Bisphosponates are medications used to treat and prevent osteoporosis; people with lupus are at an increased risk for this condition because of the inflammation they experience with the disease • Certain medications taken by lupus patients also increase the risk of osteoporosis, especially corticosteroids such as prednisone Blood pressure medications (antihypertensives) • 25% to 30% of people with lupus experience hypertension (high blood pressure); the most common causes of high blood pressure in people with lupus are kidney disease and long-term steroid use • Other medications, such as cyclosporine (Neoral, Sandimmune, Gengraf) can also cause elevations in blood pressure • It is important to remember that while diet and exercise are extremely important for optimal cardiovascular health, these elements alone may be insufficient in controlling your blood pressure; in this case, your doctor will prescribe a medication Anticoagulants • Anticoagulants (“blood thinners”) are medications that decrease the ability of the blood to clot and are used in lupus patients with antiphospholipid antibodies to reduce the risk of deep venous thrombosis (DVT), stroke, and heart attack Gastrointestinal medications • Many people with lupus suffer from gastrointestinal problems, especially heartburn caused by gastroesophageal reflux disease (GERD); peptic ulcers can also occur, often because of certain medications used in lupus treatment, including NSAIDs and steroids • Certain medications may be prescribed or recommended by your doctor to control these conditions
  • 4. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician,”at www.peerview.com/FYE40. Information for Patients: Common Medications for Other Conditions in People With Lupus1 PRACTICE AID 1. https://www.hopkinslupus.org/lupus-treatment/. Accessed May 11, 2018. Cholesterol medications (statins) • Statins are medications that lower the level of cholesterol in your blood by reducing the production of cholesterol in the liver; people with high levels of cholesterol in their blood face an increased risk of cardiovascular disease, which can lead to chest pain, heart attack, stroke, and peripheral vascular disease • Studies have shown that people with lupus are more likely to have clogged arteries that can lead to heart attack and stroke at a younger age; this increased risk is caused by elevated cholesterol levels, high blood pressure, diabetes, and inflammation, conditions that occur often in people with lupus • Certain medications, such as corticosteroids (eg, prednisone), can provoke or compound these symptoms; for this reason, the cholesterol-lowering properties of statins are commonly called upon for lupus patients Thyroid medications • Autoimmune thyroid disease is common in lupus; it is believed that about 6% of people with lupus have hypothyroidism (underactive thyroid) and about 2% have hyperthyroidism (overactive thyroid) • A thyroid gland that is functioning improperly can affect the function of organs such as the brain, heart, kidneys, liver, and skin • Hypothyroidism can cause weight gain, fatigue, depression, moodiness, and dry hair and skin; hyperthyroidism can cause weight loss, heart palpitations, tremors, and heat intolerance, and can eventually lead to osteoporosis • Treatment for both underactive and overactive thyroid involves getting your body’s metabolism back to normal Fibromyalgia medications • Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness, general fatigue, and nonrestful sleep • Many people with lupus have fibromyalgia; in fact, much of the pain that people with lupus feel is because of this condition • Three medications are used to reduce some of the physical and emotional symptoms of fibromyalgia Restasis (dry eye medication) • Restasis is an immunosuppressive medication used to treat eye symptoms related to Sjogren’s syndrome, a chronic autoimmune disorder in which the glands that produce tears and saliva do not function correctly
  • 5. Access the activity,“Improving the Diagnosis and Treatment of Lupus: Practical Guidance for the Primary Care Physician,”at www.peerview.com/FYE40. Information for Patients: Lifestyle Information1 PRACTICE AID This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. 1. https://www.hopkinslupus.org/lupus-info/lifestyle-additional-information/. Accessed May 11, 2018. THINGS TO AVOID Sunlight Echinacea Bactrim and Septra (sulfamethoxazole and trimethoprim) Alfalfa sprouts Melatonin and Rozerem (ramelteon) Garlic